2032
Arrowhead’s Plozasiran Projected to Surpass $700M in Sales by 2032, Addressing Major Unmet Needs in Dyslipidemia Treatment
Arrowhead Pharmaceuticals, Plozasiran, Dyslipidemia, GlobalData, Sales Forecast, $700M, 2032, Unmet Needs, Triglyceride Reduction, APOC3 Targeting, SHTG (Severe Hypertriglyceridemia), FCS (Familial Chylomicronemia Syndrome), Mixed Dyslipidemia